FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366084332> ?p ?o ?g. }

• W4366084332 endingPage "999" @default.
• W4366084332 startingPage "986" @default.
• W4366084332 abstract "Abstract Psoriasis and atopic dermatitis are chronic inflammatory skin conditions, each affecting about 2–3% of the United States adult population. Phototherapy, such as narrowband ultraviolet‐B (NB‐UVB) therapy have been employed for the treatment of both psoriasis and atopic dermatitis for decades. More recently, systemic biologics have been approved by the Food and Drug Administration (FDA), representing a great advancement in dermatology. No comprehensive study to date has compared the cost efficacy of phototherapy compared to FDA‐approved biologics for the treatment of psoriasis and atopic dermatitis. We pursued a systematic review of the literature for studies assessing efficacy of NB‐UVB or biologics with endpoints including the Psoriasis Area and Severity Index (PASI) and the Eczema Area and Severity Index (EASI). Thirty‐four studies including 55 treatment regimens and 5,123 patients were included in the analysis. Phototherapy costs were estimated with Medicare fee schedules for phototherapy‐related current procedural terminology code (CPT), and biologic costs were estimated with wholesale acquisition cost (WAC). Total costs to achieve PASI 75 or EASI 75 in each study were standardized to a single month, the “adjusted cost,” and exploited to a year, the “effective yearly cost,” allowing direct cost‐efficacy comparison despite different durations of treatment described in studies. The psoriasis analysis found NB‐UVB to be the most cost‐effective therapy, with an adjusted monthly cost of $1714.00 per PASI 75. Infliximab was the least expensive biologic, with an adjusted monthly cost of $2076.00 to $2502.00 per PASI 75. For atopic dermatitis, no NB‐UVB studies utilized EASI 75 as their outcome measure, hindering the ability to directly compare cost effectiveness for the treatment of atopic dermatitis. However, all NB‐UVB studies depicted a reduced treatment cost per treatment period compared to studies assessing biologics, although this comparison does not account for efficacy. The results depict NB‐UVB to be the most cost effective for the treatment of psoriasis and the least expensive per treatment period for the treatment of atopic dermatitis. However, certain factors need to be taken into account. Biologics may be more effective for more severe disease, do not require multiple weekly clinic visits, and the ease for patient compliance may lead some to favor biologic therapy. This study is necessary to allow physicians, patients, and health systems to make informed decisions regarding cost‐efficacy for a variety of treatment options." @default.
• W4366084332 created "2023-04-19" @default.
• W4366084332 creator A5013643256 @default.
• W4366084332 creator A5024693029 @default.
• W4366084332 creator A5056846021 @default.
• W4366084332 creator A5058216979 @default.
• W4366084332 creator A5071087691 @default.
• W4366084332 creator A5087592210 @default.
• W4366084332 date "2023-04-17" @default.
• W4366084332 modified "2023-10-12" @default.
• W4366084332 title "Systematic review and estimated cost‐efficacy of biologics compared with narrowband ultraviolet B light for the treatment of moderate to severe psoriasis and atopic dermatitis" @default.
• W4366084332 cites W1541270304 @default.
• W4366084332 cites W1572018981 @default.
• W4366084332 cites W1719293643 @default.
• W4366084332 cites W1845936179 @default.
• W4366084332 cites W1977487899 @default.
• W4366084332 cites W1977571789 @default.
• W4366084332 cites W1993901124 @default.
• W4366084332 cites W2023745828 @default.
• W4366084332 cites W2039018479 @default.
• W4366084332 cites W2080390872 @default.
• W4366084332 cites W2095109585 @default.
• W4366084332 cites W2099687194 @default.
• W4366084332 cites W2103750969 @default.
• W4366084332 cites W2116956799 @default.
• W4366084332 cites W2118630839 @default.
• W4366084332 cites W2126798127 @default.
• W4366084332 cites W2127834887 @default.
• W4366084332 cites W2133696182 @default.
• W4366084332 cites W2145778588 @default.
• W4366084332 cites W2146843653 @default.
• W4366084332 cites W2151209321 @default.
• W4366084332 cites W2158163176 @default.
• W4366084332 cites W2168911501 @default.
• W4366084332 cites W2174132185 @default.
• W4366084332 cites W2276035339 @default.
• W4366084332 cites W2322390243 @default.
• W4366084332 cites W2532238474 @default.
• W4366084332 cites W2623888527 @default.
• W4366084332 cites W2775506923 @default.
• W4366084332 cites W2797238574 @default.
• W4366084332 cites W2955490990 @default.
• W4366084332 cites W2964703987 @default.
• W4366084332 cites W2969960972 @default.
• W4366084332 cites W2973122049 @default.
• W4366084332 cites W3091046625 @default.
• W4366084332 cites W3093227824 @default.
• W4366084332 cites W3145364546 @default.
• W4366084332 cites W3206039614 @default.
• W4366084332 cites W3209422551 @default.
• W4366084332 cites W4214568086 @default.
• W4366084332 doi "https://doi.org/10.1111/ijd.16677" @default.
• W4366084332 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37066447" @default.
• W4366084332 hasPublicationYear "2023" @default.
• W4366084332 type Work @default.
• W4366084332 citedByCount "0" @default.
• W4366084332 crossrefType "journal-article" @default.
• W4366084332 hasAuthorship W4366084332A5013643256 @default.
• W4366084332 hasAuthorship W4366084332A5024693029 @default.
• W4366084332 hasAuthorship W4366084332A5056846021 @default.
• W4366084332 hasAuthorship W4366084332A5058216979 @default.
• W4366084332 hasAuthorship W4366084332A5071087691 @default.
• W4366084332 hasAuthorship W4366084332A5087592210 @default.
• W4366084332 hasConcept C126322002 @default.
• W4366084332 hasConcept C16005928 @default.
• W4366084332 hasConcept C2777011040 @default.
• W4366084332 hasConcept C2777138892 @default.
• W4366084332 hasConcept C2778329239 @default.
• W4366084332 hasConcept C2779134260 @default.
• W4366084332 hasConcept C2780564577 @default.
• W4366084332 hasConcept C2780699399 @default.
• W4366084332 hasConcept C2908647359 @default.
• W4366084332 hasConcept C2910796831 @default.
• W4366084332 hasConcept C3020604521 @default.
• W4366084332 hasConcept C71924100 @default.
• W4366084332 hasConcept C99454951 @default.
• W4366084332 hasConceptScore W4366084332C126322002 @default.
• W4366084332 hasConceptScore W4366084332C16005928 @default.
• W4366084332 hasConceptScore W4366084332C2777011040 @default.
• W4366084332 hasConceptScore W4366084332C2777138892 @default.
• W4366084332 hasConceptScore W4366084332C2778329239 @default.
• W4366084332 hasConceptScore W4366084332C2779134260 @default.
• W4366084332 hasConceptScore W4366084332C2780564577 @default.
• W4366084332 hasConceptScore W4366084332C2780699399 @default.
• W4366084332 hasConceptScore W4366084332C2908647359 @default.
• W4366084332 hasConceptScore W4366084332C2910796831 @default.
• W4366084332 hasConceptScore W4366084332C3020604521 @default.
• W4366084332 hasConceptScore W4366084332C71924100 @default.
• W4366084332 hasConceptScore W4366084332C99454951 @default.
• W4366084332 hasIssue "8" @default.
• W4366084332 hasLocation W43660843321 @default.
• W4366084332 hasLocation W43660843322 @default.
• W4366084332 hasOpenAccess W4366084332 @default.
• W4366084332 hasPrimaryLocation W43660843321 @default.
• W4366084332 hasRelatedWork W2060817629 @default.
• W4366084332 hasRelatedWork W2124441198 @default.
• W4366084332 hasRelatedWork W2520935772 @default.
• W4366084332 hasRelatedWork W2602145888 @default.

• next